# US 11,998,643 B2 · Nanostructure lipid system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,643 B2
- Document ID: US11998643B2
- Status: Granted
- Kind: B2
- Application number: 17/259,110
- Filed: 2019-07-10
- Published: 2021-10-21
- Granted: 2024-06-04
- Earliest claimed: 2018-07-10
- Assignees: Universidade De Santiago De Compostela; Servizo Galego De SAúDe; FundacióN Instituto De InvestigacióN Sanitaria De Santiago De Compostela (Fidis)
- Applicants: Universidade De Santiago De Compostela; FundacióN Instituto De InvestigacióN Sanitaria De Santiago De Compostela (Fidis); Servizo Galego De SAúDe
- Inventors: José Víctor Álvarez González; Francisco Javier Otero Espinar; Mª Luz Couce Pico; Asteria Luzardo Álvarez; Cristobal Colón Mejeras; MªRosaura Leis Trabazo
- Web page: https://patentgrep.com/patent/US11998643B2

## CPC

- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5089: {Processes}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 19/04: for non-specific disorders of the connective tissue
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to systems of administration of enzymes or other proteins, preferably for use in enzyme replacement therapy (ERT), in particular for the treatment of Lysosomal diseases. In particular, the invention encompasses the preparation of a composition based on nanostructured lipid systems and its use in the manufacture of a therapeutic product.

## Claims

### Claim 1

A lipid nanostructured system which comprises nanoparticles which in turn comprise:
a. a gelled core comprising an aqueous dissolution, solution or dispersion comprising a temperature responsive polymer that becomes a gel as a function of the temperature, and which further comprises one or more enzymes or other proteins immobilized in the core;
b. a lipid layer coating the inner core comprising a mixture of:
i. a solid lipid, which is solid or waxy at 25° C. and a pressure of 1 atm, comprising fatty acids, with a fusion process that begins at temperatures above 35° C., as determined by differential scanning calorimetry (DSC), with a hydrophilic-lipophilic balance (HLB) value lower than 10 and densities between 0.8 and 1 g/cm3, or a mixture of the solid lipids, and
ii. a liquid lipid which behaves as a liquid at 25° C. and a pressure of 1 atm, constituted by fatty acids with a fusion process that begins at temperatures below 30° C., as determined by differential scanning calorimetry (DSC), and densities ranging from 0.88 to 0.97 g/cm3,
where the mixture of liquid lipid and solid lipid presents a fusion process that begins at temperatures between 20° C. and below 50° C. as determined by differential scanning calorimetry (DSC), wherein the solid lipid and liquid lipid are mixed in a ratio of liquid lipid to solid lipid of 98:2 to 1:99%, wherein the ratio is expressed as a percentage by weight of solid lipid and liquid lipid with respect to the total lipid composition of the lipid layer coating the inner core;
wherein the lipid layer also comprises lipid soluble or dispersible surfactants; wherein the lipid soluble or lipid dispersible surfactants, are selected from molecules surface-active with HLB values lower than 10; and
c. a pegylated coating of the lipid layer that also comprises water soluble or water dispersible surfactants, wherein said pegylated coating comprises polyethylene glycol (PEG), or PEG esters, and the water soluble or water dispersible surfactants have a HLB greater than 10.

### Claim 2 (depends on 1)

The lipid system of claim 1, wherein fatty acids of the lipid layer comprise the following formula:
C:D n−x,
wherein:
C represents the number of carbon atoms of the fatty acid;
D is the number of double bonds in the fatty acid;
n is the position of a distal double bond, where n is the total number of carbons and x a number provided by the position, and wherein any multiple double bonds are separated by a methylene group;
wherein the solid lipid is selected from the group consisting of:
a. saturated fatty acids that have values of C≥12 and C<41 and D=0;
b. unsaturated and polyunsaturated trans fatty acids with values of C>17y C<25, D≥1, x between 1 and n−2;
c. monoesters of fatty acids saturated with values of C≥14 and C<41 and D=0 with sorbitan, polyoxyethylene, polioxietilensorbitano, glycerine or diethylene glycol;
d. triesters formed between glycerol and fatty acids saturated with values of C≥3 and C<41 and D=0;
e. triesters formed between glycerol and trans unsaturated fatty acids; and
f. any combination thereof; and
wherein the liquid lipid is selected from the group consisting of:
a. saturated fatty acids that have values of C≥3 and C≤11 and D=0;
b. unsaturated and polyunsaturated cis acid fatty with values of C≥3 and C≤23, D≥1, x between 1 and n−2;
c. monoesters of fatty acids saturated with values of C≥3 and C<14 y D=0 with sorbitan, polyoxyethylene, polyoxyethylensorbitane, glycerin or diethylene glycol;
d. triesters formed between glycerol and fatty acids saturated with values of C<3 and D=0
e. triesters formed between glycerin and unsaturated cis fatty acids with values of C≥3 y C≤23, D≥1, x between 1 and n−2; and
f. any combination thereof.

### Claim 3 (depends on 1)

The lipid system of claim 1, where the lipid layer is made of a mixture of solid and liquid lipids in a ratio between 30:70 and 50:50, and wherein the mixture presents a fusion process that starts at temperatures between 30 and 40° C., as determined by differential scanning calorimetry (DSC).

### Claim 4 (depends on 1)

The lipid system of claim 1, wherein the lipid layer is made up of a mixture of solid and liquid lipids in a ratio between 35:65 and 45:55, and the mixture has a fusion process that begins at temperatures between 35 and 40° C., as determined by differential scanning calorimetry (DSC).

### Claim 5 (depends on 1)

The lipid system of claim 1, where the dissolution solution, or dispersion of aqueous nature of the core comprises a temperature responsive polymer selected from the group consisting of: poloxamer 407, Chitosan, hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC) and diblock copolymer of polyethylene glycol and polylactic acid (PLGA-PEG-PEG).

### Claim 6 (depends on 1)

The lipid system of claim 1 wherein the gelled core comprises one or more enzymes selected from group list consisting of: elosulfase alfa, velaglucerase, laronidase, idursulfase, galsulfase, imiglucerase, agalsidase, sebelipase alfa, cerliponase alfa, velmanase and alglucosidase, immobilized in the core.

### Claim 7 (depends on 1)

The lipid system of claim 1, where the solid lipid is selected from the group consisting of: glyceryl disterate, glyceryl palmitosterate, trimyristin, tristearin, cholesterol, soy lecithin, egg lecithin, sunflower lecithin and corn lecithin; and the liquid lipid is selected from the group consisting of: olive oil and triglycerides of caprilic and capric acids.

### Claim 8 (depends on 1)

The lipid system of claim 1, wherein the lipid layer is made of a mixture of glyceryl disterate or glycerol palmitate in an amount ranging from 5-20%, with trimyristin in an amount between 5-20%, tristearin in an amount between 5-20%, and cholesterol in an amount between 2-10%, as solid components, and soy lecithin and a blend of liquid components comprising olive oil in an amount between 30-70%, and triglycerides of caprilic and capric acids in an amount between a 10-20%, wherein the percentage of each component, refers to its proportion in weight/weight percentage with respect to the total amount of lipids that form the layer.

### Claim 9 (depends on 1)

The lipid system of claim 1, wherein the lipid layer is made of a mixture of dibehenate of glyceryl in an amount ranging from 5-20%, with trimyristin in an amount between 5-20%, tristearin in an amount between 5-20%, and cholesterol in an amount between 2-10% as solid components and egg lecithin or soy lecithin, and a blend of liquid lipid as olive oil, cod liver oil or sunflower oil in an amount between 30-70% and triglycerides of caprilic and capric acids in an amount between a 10-20%, wherein % refers to weight/weight percentage of each component related to the total amount of lipids forming the layer.

### Claim 10 (depends on 1)

The lipid system of claim 1, wherein the lipid layer that coats the aqueous core is formed by mixtures of the following solid and liquid lipids: glyceryl dibehenate, glyceryl, Tristearin, Trimyristine, Cholesterol, olive oil, triglycerides of caprylic and capric acid and liquid soy lecithin.

### Claim 11 (depends on 1)

The lipid system of claim 1, wherein the gelled core comprises one or more proteins with activity on cellular metabolism selected from the group consisting of infliximab, abatacerpt, rituximab, adalidumab, etanercept, golimumab, certolizumab, sifalimumab, and anifrolumab, immobilized in the core.

### Claim 12 (depends on 1)

A method for delivering an enzyme or protein for therapy of a subject in need thereof, comprising administering the nanostructured lipid system of claim 1 to the subject.

### Claim 13 (depends on 1)

A method for the treatment or prevention of the degeneration of the cartilage or bone or for treatment of a lysosomal storage disease, comprising administering the nanostructured lipid system of claim 1 to a subject in need thereof.